{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:39:48Z","timestamp":1778812788307,"version":"3.51.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:p>Acidity is a useful biomarker for the targeting of metabolically active cells in tumors. pH Low Insertion Peptides (pHLIPs) sense the pH at the surfaces of tumor cells and can facilitate intracellular delivery of cell-permeable and cell-impermeable cargo molecules. In this study we have shown the targeting of malignant lesions in human bladders by fluorescent pHLIP agents, intracellular delivery of amanitin toxin by pHLIP for the inhibition of urothelial cancer cell proliferation, and enhanced potency of pHLIP-amanitin for cancer cells with 17p loss, a mutation frequently present in urothelial cancers. Twenty-eight <jats:italic>ex-vivo<\/jats:italic> bladder specimens, from patients undergoing robotic assisted laparoscopic radical cystectomy for bladder cancer, were treated <jats:italic>via<\/jats:italic> intravesical incubation for 15-60 minutes with pHLIP conjugated to indocyanine green (ICG) or IR-800 near infrared fluorescent (NIRF) dyes at concentrations of 4-8 \u03bcM. White light cystoscopy identified 47\/58 (81%) and NIRF pHLIP cystoscopy identified 57\/58 (98.3%) of malignant lesions of different subtypes and stages selected for histopathological processing. pHLIP NIRF imaging improved diagnosis by 17.3% (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). All carcinoma-<jats:italic>in-situ<\/jats:italic> cases missed by white light cystoscopy were targeted by pHLIP agents and were diagnosed by NIRF imaging. We also investigated the interactions of pHLIP-amanitin with urothelial cancer cells of different grades. pHLIP-amanitin produced concentration- and pH-dependent inhibition of the proliferation of urothelial cancer cells treated for 2 hrs at concentrations up to 4 \u03bcM. A 3-4x enhanced cytotoxicity of pHLIP-amanitin was observed for cells with a 17p loss after 2 hrs of treatment at pH6. Potentially, pHLIP technology may improve the management of urothelial cancers, including imaging of malignant lesions using pHLIP-ICG for diagnosis and surgery, and the use of pHLIP-amanitin for treatment of superficial bladder cancers <jats:italic>via<\/jats:italic> intravesical instillation.<\/jats:p>","DOI":"10.3389\/fruro.2022.868919","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T12:07:37Z","timestamp":1661429257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting bladder urothelial carcinoma with pHLIP-ICG and inhibition of urothelial cancer cell proliferation by pHLIP-amanitin"],"prefix":"10.3389","volume":"2","author":[{"given":"Anna","family":"Moshnikova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borivoj","family":"Golijanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad","family":"Kott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gershman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongbin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M.","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg A.","family":"Andreev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana K.","family":"Reshetnyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Golijanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2015.1033610","article-title":"Molecular markers in bladder cancer: Novel research frontiers","volume":"52","author":"Sanguedolce","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2449-8","article-title":"The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)","volume":"143","author":"Nicolazzo","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk nonmuscle-invasive bladder cancer: A systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Focus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41585-019-0220-4","article-title":"Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer","volume":"16","author":"Joice","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2017.03.014","article-title":"Applications of pHLIP technology for cancer imaging and therapy","volume":"35","author":"Wyatt","year":"2017","journal-title":"Trends Biotechnol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00335","article-title":"Targeting acidic diseased tissues by pH-triggered membrane-associated peptide folding","volume":"8","author":"Reshetnyak","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1529\/biophysj.107.109967","article-title":"A monomeric membrane peptide that lives in three worlds: in solution, attached to, and inserted across lipid bilayers","volume":"93","author":"Reshetnyak","year":"2007","journal-title":"Biophys J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914330107","article-title":"pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exits by a different path","volume":"107","author":"Andreev","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/bi970147b","article-title":"Spontaneous, pH-dependent membrane insertion of a transbilayer alpha-helix","volume":"36","author":"Hunt","year":"1997","journal-title":"Biochemistry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610472113","article-title":"Targeted imaging of urothelium carcinoma in human bladders by an ICG pHLIP peptide ex vivo","volume":"113","author":"Golijanin","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.01.008","article-title":"Ex-vivo imaging of upper tract urothelial carcinoma using novel pH low insertion peptide (Variant 3), a molecular imaging probe","volume":"139","author":"Brito","year":"2020","journal-title":"Urology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/bi301647y","article-title":"Antiproliferative effect of pHLIP-amanitin","volume":"52","author":"Moshnikova","year":"2013","journal-title":"Biochemistry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31322","DOI":"10.1038\/srep31322","article-title":"Novel pH-sensitive cyclic peptides","volume":"6","author":"Weerakkody","year":"2016","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1715350115","article-title":"Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors","volume":"115","author":"Wyatt","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014403107","article-title":"pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation","volume":"107","author":"An","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/bi2009773","article-title":"Tuning a polar molecule for selective cytoplasmic delivery by a pH (Low) insertion peptide","volume":"50","author":"Wijesinghe","year":"2011","journal-title":"Biochemistry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/bjc.1978.164","article-title":"Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma","volume":"38","author":"O'Toole","year":"1978","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)45139-1","article-title":"Improved growth of human urothelial carcinoma cell cultures","volume":"136","author":"Grossman","year":"1986","journal-title":"J Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910170604","article-title":"A cell line (SCABER) derived from squamous cell carcinoma of the human urinary bladder","volume":"17","author":"O'Toole","year":"1976","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910110327","article-title":"Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen","volume":"11","author":"Bubenik","year":"1973","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.21","article-title":"A cell line from an anaplastic transitional cell carcinoma of human urinary bladder","volume":"35","author":"Nayak","year":"1977","journal-title":"Br J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1970.89","article-title":"A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure","volume":"24","author":"Rigby","year":"1970","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/58.4.881","article-title":"Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses","volume":"58","author":"Rasheed","year":"1977","journal-title":"J Natl Cancer Inst"},{"key":"B26","first-page":"5","article-title":"Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors","volume":"49","author":"Fogh","year":"1978","journal-title":"Natl Cancer Inst Monogr"},{"key":"B27","article-title":"Human urologic cancer cell lines","volume":"17","author":"Williams","year":"1980","journal-title":"Invest Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608247113","article-title":"Probe for the measurement of cell surface pH in vivo and ex vivo","volume":"113","author":"Anderson","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-019-01335-4","article-title":"Mapping pH at cancer cell surfaces","volume":"21","author":"Wei","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1039\/D0CC06694J","article-title":"Amphiphilic fluorescent probe self-encored in plasma to detect pH fluctuations in cancer cell membranes","volume":"57","author":"Podder","year":"2021","journal-title":"Chem Commun (Camb)"},{"key":"B31","article-title":"Hypoxia-inducible expression of tumor-associated carbonic anhydrases","volume":"60","author":"Wykoff","year":"2000","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.bjc.6600936","article-title":"Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer","volume":"89","author":"Potter","year":"2003","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.006478","article-title":"The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths","volume":"284","author":"Swietach","year":"2009","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0403","article-title":"PKM2 is essential for bladder cancer growth and maintenance","volume":"82","author":"Xia","year":"2022","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10090.x","article-title":"Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study","volume":"108","author":"Hermann","year":"2011","journal-title":"BJU Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08788.x","article-title":"Narrow-band imaging cystoscopy to evaluate the response to bacille calmette-guerin therapy: preliminary results","volume":"105","author":"Herr","year":"2010","journal-title":"BJU Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.01.018","article-title":"A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence","volume":"61","author":"Naselli","year":"2012","journal-title":"Eur Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.04.013","article-title":"Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry","volume":"36","author":"Daneshmand","year":"2018","journal-title":"Urol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non\u2013muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2016.05.001","article-title":"Narrow band imaging for bladder cancer","volume":"3","author":"Hsueh","year":"2016","journal-title":"Asian J Urol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ucl.2015.01.001","article-title":"Advances in imaging technologies in the evaluation of high-grade bladder cancer","volume":"42","author":"Zlatev","year":"2015","journal-title":"Urol Clin North Am"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-013-0068-x","article-title":"Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer","volume":"18","author":"Yang","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12917","article-title":"Short-term pretreatment with a dual 5alpha-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates","volume":"116","author":"Busetto","year":"2015","journal-title":"BJU Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02515-x","article-title":"Interplay between male testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission","volume":"70","author":"Salciccia","year":"2020","journal-title":"Endocrine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0041-0101(97)00074-3","article-title":"Toxins of amanita phalloides","volume":"36","author":"Vetter","year":"1998","journal-title":"Toxicon"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201903498","article-title":"The role of organic synthesis in the emergence and development of antibody-drug conjugates as targeted cancer therapies","volume":"58","author":"Nicolaou","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs140","article-title":"Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma","volume":"104","author":"Moldenhauer","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.6115471","article-title":"A conjugate of alpha-amanitin and monoclonal immunoglobulin G to thy 1.2 antigen is selectively toxic to T lymphoma cells","volume":"213","author":"Davis","year":"1981","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(86)90502-X","article-title":"Characterization of a transporting system in rat hepatocytes. studies with competitive and non-competitive inhibitors of phalloidin transport","volume":"860","author":"Munter","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc6894","article-title":"Targeted immunotherapy for HER2-low breast cancer with 17p loss","volume":"13","author":"Li","year":"2021","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36977-X","article-title":"Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype","volume":"148","author":"Habuchi","year":"1992","journal-title":"J Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910530409","article-title":"Accumulated allelic losses in the development of invasive urothelial cancer","volume":"53","author":"Habuchi","year":"1993","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nature14418","article-title":"TP53 loss creates therapeutic vulnerability in colorectal cancer","volume":"520","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/02841868809090314","article-title":"Pharmacokinetics of doxorubicin in man with induced acid or alkaline urine","volume":"27","author":"Krarup-Hansen","year":"1988","journal-title":"Acta Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00869.x","article-title":"The effect of fasting or desmopressin before treatment on the concentration of mitomycin c during intravesical administration","volume":"86","author":"Cliff","year":"2000","journal-title":"BJU Int"},{"key":"B59","doi-asserted-by":"publisher","first-page":"zcab021","DOI":"10.1093\/narcan\/zcab021","article-title":"Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity","volume":"3","author":"Gayle","year":"2021","journal-title":"NAR Cancer"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2022.868919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T12:07:43Z","timestamp":1661429263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2022.868919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":59,"alternative-id":["10.3389\/fruro.2022.868919"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2022.868919","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"868919"}}